Brian DeSchuytner
2020
In 2020, Brian DeSchuytner earned a total compensation of $950.3K as Senior Vice President, Finance & Product Strategy at Mersana Therapeutics, a 6% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $181,610 |
|---|---|
| Option Awards | $272,724 |
| Salary | $391,400 |
| Stock Awards | $97,531 |
| Other | $7,000 |
| Total | $950,265 |
DeSchuytner received $391.4K in salary, accounting for 41% of the total pay in 2020.
DeSchuytner also received $181.6K in non-equity incentive plan, $272.7K in option awards, $97.5K in stock awards and $7K in other compensation.
Rankings
In 2020, Brian DeSchuytner's compensation ranked 8,847th out of 13,090 executives tracked by ExecPay. In other words, DeSchuytner earned more than 32.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,847 out of 13,090 | 32nd |
Division Manufacturing | 3,774 out of 5,621 | 33rd |
Major group Chemicals And Allied Products | 1,525 out of 2,254 | 32nd |
Industry group Drugs | 1,328 out of 1,954 | 32nd |
Industry Pharmaceutical Preparations | 982 out of 1,459 | 33rd |
Source: SEC filing on April 27, 2021.
DeSchuytner's colleagues
We found four more compensation records of executives who worked with Brian DeSchuytner at Mersana Therapeutics in 2020.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Mersana Therapeutics CEO Anna Protopapas' 2022 pay falls 66% to $2.8M
April 28, 2023
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020